卓正医疗
Distinct HealthCare

Distinct Healthcare Holdings Limited
卓正医疗控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2677)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

FINANCIAL HIGHLIGHTS

	Six months ended June 30,		
	2026	2025	Year-on-year change
	RMB'000	*RMB'000*	*%*
	(Unaudited)	(Unaudited)	
Revenue	**595,909**	509,268	17.0
Gross profit	**162,399**	115,582	40.5
Gross profit margin (%)	**27.3**	22.7	N/A
Net profit	**83,390**	75,467	10.5
Non-IFRS adjusted net profit/(loss)(1)	**28,402**	(569)	5,091.6
Non-IFRS adjusted operating profit(2)	**38,808**	3,740	937.6
Non-IFRS adjusted EBITDA(3)	**103,768**	71,323	45.5
Earnings/(losses) per share (in RMB)			
– Basic	**1.71**	5.55	
– Diluted	**0.29**	*	

Notes:

(1) Non-IFRS adjusted net profit/(loss) is calculated as net profit/(loss), excluding (i) fair value gain of convertible redeemable preference shares; and (ii) listing expenses.

(2) Non-IFRS adjusted operating profit is calculated as operating profit, excluding listing expenses.

(3) Non-IFRS adjusted EBITDA is calculated as Non-IFRS adjusted operating profit, excluding (i) depreciation of property, plant and equipment; (ii) depreciation of right-of-use assets; and (iii) amortization of intangible assets.

* The losses per share is negative 0.0049.

Non-IFRS Measures

To supplement the consolidated financial statements of the Group presented in accordance with IFRS, the Company has presented adjusted net profit/(loss), adjusted operating profit, and adjusted EBITDA as non-IFRS measures, which are not required by or presented in accordance with IFRS. The Company believes that adjusted financial measures provide useful information to the Shareholders and potential investors to understand and evaluate the consolidated statement of profit and loss of the Group and assist the management of the Company in its decision making. The Company believes that by eliminating the effects of items that it believes are not indicative of the Group's operating performance, such adjusted financial measures assist the management of the Company and investors to evaluate the financial and operating performance of the Group for different periods on a comparable basis. However, these non-IFRS measures should not be considered independently or as a substitute for financial information prepared and presented in accordance with IFRS. Shareholders and potential investors should not independently evaluate such adjusted results or regard it as a substitute for, or comparable to, performance reported or forecasted by other companies, as they may use similar terms with different meanings. In addition, these non-IFRS measures have their limitations as analytical tools and may differ from similar measures used by other companies.

The table below sets forth the reconciliation of our non-IFRS measures presented in accordance with IFRS for the periods indicated:

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Net profit	**83,390**	75,467
Adjustments:		
Fair value gain of convertible redeemable preference shares	**(68,412)**	(77,622)
Listing expenses	**13,424**	1,586
Non-IFRS adjusted net profit/(loss)	**28,402**	(569)
Operating profit	**25,384**	2,154
Adjustments:		
Listing expenses	**13,424**	1,586
Non-IFRS adjusted operating profit	**38,808**	3,740
Non-IFRS adjusted operating profit	**38,808**	3,740
Adjustments:		
Depreciation of property, plant and equipment	**28,304**	30,943
Depreciation of right-of-use assets	**36,071**	36,068
Amortization of intangible assets	**585**	572
Non-IFRS adjusted EBITDA	**103,768**	71,323

MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS REVIEW

China's healthcare service market is continuously evolving towards quality, personalization, and long-cycle health management. As consumer health needs extend from single consultations to prevention, health management, and full-life-cycle services, the demand for high-quality, multi-specialty, one-stop health services continues to rise. As a leading brand in high-quality, digitally-enabled healthcare services in China, the Group adheres to its core philosophy of Evidence-Based Medicine and Whole-Person Care, focusing on its membership base. We continue to enhance our integrated online-offline healthcare service system to provide users with multi-specialty, multi-scenario, and full-life-cycle healthcare services.

In the first half of 2026, the Group continued to pursue its user-centric development strategy, focusing on key strategies such as the development of One-stop Healthcare Service Institutions, the enhancement of multi-specialty service capabilities, long-term membership operations, and the development of artificial intelligence ("**AI**") capabilities. By persistently improving offline service delivery capacity, refining multi-specialty collaboration models, and deepening user relationships, the Group is gradually establishing a sustainable growth model driven by user scale expansion, increased per-user value, and enhanced operational efficiency.

In the first half of 2026, the Group achieved revenue of RMB595.9 million, representing a year-on-year increase of 17.0%. Revenue from in-person healthcare services amounted to RMB549.7 million, up 17.6% year-on-year, while revenue from in-person healthcare services (excluding contributions from acquisitions) was RMB543.6 million, representing an organic growth of 28.8% year-on-year. This revenue growth was primarily driven by the expansion of One-stop Healthcare Service Institution network and the enhancement of its service capabilities, the sustained release of demand for multi-specialty services, and the increasing scale of our membership base and long-term user value. During the Reporting Period, the Group continued to upgrade its Initial Standard Institutions into One-stop Healthcare Service Institutions, enhancing service capacity and optimizing services offerings to better meet the diverse health needs of families. Concurrently, through the development of signature services, cross-specialty member engagement, and the deepening of our membership system, we have consistently enhanced user visit frequency, cross-specialty service penetration, and customer lifetime value.

In terms of profitability and cash flow, the Group continued to improve its operational quality and economies of scale. In the first half of 2026, the Group's gross profit margin increased from 22.7% in the same period of 2025 to 27.3%, representing an increase of 4.6 percentage points. It achieved an adjusted operating profit (a non-IFRS measure) of RMB38.8 million, with an adjusted operating profit margin of 6.5%, representing an increase of 5.8 percentage points. The rapid growth in the Group's adjusted operating profit was mainly attributable to the improved operational efficiency and profitability brought by the ongoing optimization of the institution mix as the number of One-stop Healthcare Service Institutions increased, combined with the economies of scale from revenue growth. Furthermore, digital and AI capabilities continued to empower business operations, improving the efficiency of human resource utilization and steadily reducing the ratio of personnel costs to revenue. The Group's net cash generated from operating activities was RMB65.2 million, up 18.0% year-on-year.

Looking ahead, the Group will continue to focus on high-quality healthcare services, targeting quality-conscious healthcare service users such as professional elites and their families. We will persist in enhancing our One-stop Healthcare Service Institution network, multi-specialty collaboration capabilities, membership system, and digital platform to promote cross-specialty and cross-lifecycle service extension for our users. Simultaneously, the Group will actively explore innovative models such as subscription-based health services, personalized AI health assistants, and ecosystem partnerships. Through our integrated online-offline service capabilities, we aim to build a service loop covering prevention, diagnosis, and long-term health management. This will deepen our long-term relationships with users, enhancing their lifetime value and our operational quality.

Network Upgrading: Continuously Improving the One-stop Healthcare Service Institution Network and Steadily Advancing Upgrades and New Openings

The Group is steadily advancing various upgrade and new construction projects according to plan, with progress in line with management's expectations. By combining upgrades of existing institutions with the addition of new ones, the Group is continuously enhancing its offline service network and the service capacity of individual institutions to further meet the multi-specialty, one-stop health service needs of user families, laying the foundation for long-term organic growth.

As of June 30, 2026, the Group operated 18 multi-specialty service institutions in Mainland China, comprising 4 One-stop Healthcare Service Institutions and 14 Initial Standard Institutions. We are consistently advancing the upgrade of Initial Standard Institutions into One-stop Healthcare Service Institutions while concurrently opening new institutions in areas with demand, gradually expanding our health service network coverage.

During the Reporting Period, the Suzhou Huxi Clinic completed its upgrade to a One-stop Healthcare Service Institution, adding sub-specialties such as Child Development and Behavior, Child Language Assessment and Training, and Child Psychology. It also upgraded its adult health management and check-up service capabilities and established a new Rehabilitation Medicine Center and a Mental Health Department. Furthermore, three One-stop Healthcare Service Institutions in Changsha, Wuhan, and Shenzhen have substantially completed renovation and are expected to commence operations sequentially in the third quarter of 2026. With the opening of these institutions, the number of our One-stop Healthcare Service Institutions will further increase. Concurrently, the Group opened a new Initial Standard Institution in Xi'an in June 2026, marking a key node in its strategic expansion into this new city.

A One-stop Healthcare Service Institution is positioned as a facility of approximately 5,000 sq.m. or more, equipped with commonly used family multi-specialty services covering well-child check-ups and pediatrics, dentistry, eye care, dermatology and medical aesthetics, adult health management and check-ups, and rehabilitation therapy, catering to the health needs of different family members across their life cycles. Through a centralized, multi-specialty service model, user families can address multiple health needs in a single visit, enhancing convenience and the overall service experience. Meanwhile, multi-specialty collaborative services and the long-term trust accumulated with users continuously increase cross-specialty service penetration, average annual visit frequency, and customer lifetime value, forming a sustainable engine for organic growth.

Institution Types and Numbers (Mainland China)

Institution Type	One-stop Healthcare Service Institution	Initial Standard Institution
GFA	~5,000 ㎡	1,000~2,000 ㎡
Scope of Services		
As of June 30, 2026	**4 institutions** (Shenzhen Bay Institution, Guangzhou Jinsui Road Institution, Chengdu High-tech Zone Institution, Suzhou Huxi Institution) 22,204 ㎡	**14 institutions** 32,694 ㎡
As of December 31, 2025	**3 institutions** (Shenzhen Bay Institution, Guangzhou Jinsui Road Institution, Chengdu High-tech Zone Institution) 18,652 ㎡	**15 institutions** 35,917 ㎡

Geographic Distribution of Institutions



Note: Besides our network in mainland China, as of June 30, 2026, we operated three GP clinics in Singapore and one GP clinic in Kuala Lumpur, Malaysia respectively.

One-stop Healthcare Service Institutions have become a key growth driver. Compared to Initial Standard Institutions, these centers, with their more comprehensive services offerings and greater service capacity, are better equipped to address the diverse and full-life-cycle health needs of user families. On the one hand, multi-specialty services help increase cross-department visit rates and average annual visit frequency for user families. On the other hand, as services such as dentistry, eye care, medical aesthetics, and adult health management continue to improve, the per-visit and annual health spending per user also continue to rise. Consequently, One-stop Healthcare Service Institutions possess greater revenue growth potential, making them an important driver for the Group's sustained revenue growth.

Region	City Tier	Six months ended June 30,	
		2026	2025
		RMB'000	*RMB'000*
Shenzhen	Tier-One	**155,063**	116,692
Guangzhou	Tier-One	**116,617**	90,303
Beijing	Tier-One	**57,568**	40,955
Shanghai	Tier-One	**38,174**	26,845
Chengdu	NewTier-One	**56,743**	49,048
Suzhou	NewTier-One	**30,526**	23,889
Changsha	NewTier-One	**23,417**	19,442
Hangzhou	NewTier-One	**20,704**	17,376
Wuhan	NewTier-One	**26,110**	61,873
Chongqing	NewTier-One	**11,804**	10,625
Foshan	Tier-Two	**8,881**	7,014
Xi'an	Tier-Two	**81**	–
Overseas	N/A	**4,004**	3,425
Total In-person Healthcare Services		**549,692**	467,487

Rather than relying on the continuous addition of new institutions to drive scale growth, the Group places greater emphasis on building one-stop service capabilities and enhancing service depth at existing institutions to unlock the long-term revenue growth potential of each location. With One-stop Healthcare Service Institutions in Changsha, Wuhan, and Shenzhen set to commence operations in the third quarter of 2026, our One-stop Healthcare Service Institution network will be further strengthened. We believe that as more institutions gradually complete the upgrade, these One-stop Healthcare Service Institutions will continuously drive growth in user scale, visit frequency, and per-user value, providing sustained momentum for the Group's future revenue growth.

Specialty Development: Enhance Multi-specialty Service Capabilities to Address User Needs, Unlock Long-term User Lifetime Value

Centered on the development of One-stop Healthcare Service Institutions, the Group consistently focuses on user needs and full-life-cycle health management, continuously improving its multi-specialty service capabilities. Our growth is not reliant on a single department but is driven by enriching the supply of family health services, increasing cross-specialty visit rates, visit frequency, and annual health spending per user. This approach continuously enhances customer lifetime value, leading to sustained revenue growth across all departments.

Specialty	Six months ended June 30, **2026** *RMB'000*	2025 *RMB'000*
Revenue		
Well-child Check-ups and Pediatrics	**83,764**	94,252
Dentistry	**115,996**	78,072
Eye Care	**77,923**	51,211
Dermatology and Medical Aesthetics	**129,260**	102,781
ENT & General Surgery	**30,140**	54,560
Adult Health Management and Health Check-ups	**89,534**	70,645
Physical Therapy	**10,699**	6,356
Mental Health	**8,336**	4,935
Others	**4,039**	4,674
Total In-person Healthcare Services	**549,692**	467,487
Total Patient Visit		
Well-child Check-ups and Pediatrics	**118,951**	121,413
Dentistry	**95,411**	72,063
Eye Care	**82,512**	59,951
Dermatology and Medical Aesthetics	**36,000**	31,127
ENT & General Surgery	**29,400**	34,917
Adult Health Management and Health Check-ups	**66,984**	57,360
Physical Therapy	**11,666**	6,325
Mental Health	**6,694**	3,957
Others	**9,137**	8,109
Total	**456,755**	395,222
Average Spending Per Patient Visit (RMB)		
Well-child Check-ups and Pediatrics	**704**	776
Dentistry	**1,216**	1,083
Eye Care	**944**	854
Dermatology and Medical Aesthetics	**3,591**	3,302
ENT & General Surgery	**1,025**	1,563
Adult Health Management and Health Check-ups	**1,337**	1,232
Physical Therapy	**917**	1,005
Mental Health	**1,245**	1,247
Others	**442**	576
Total	**1,203**	1,183

During the Reporting Period, the Group consistently strengthened its departmental service capabilities, including physician team development, equipment enhancement, and service process optimization. In pediatric care, we continued to deepen sub-specialty development to improve specialized diagnostic and treatment capabilities. In adult health management, we further refined our integrated health management service system around five key areas: chronic disease management; anti-aging and perimenopause management; sports medicine and physical therapy; mental health and sleep; and nutrition and weight management, thereby expanding the depth and breadth of services for adult users.

Beyond improving service supply, the Group also optimized departmental operational strategies centered on signature services and user lifecycle management. We use core traffic-generating products as key entry points for users to access different departments. At the same time, through scenario and product design, joint appointment scheduling, and refined membership operations, we facilitate the natural flow of users between departments, increasing cross-specialty penetration.



For example:

- Signature Services: Continuously developing signature services that are standardized, high-frequency, and meet common needs.

  Dental cleaning service for the adult: in the first half of 2026, sales volume of 27,774 units, up 95% year-on-year, bringing approximately 56% more new customers to the adult dentistry department.

  IPL (Intense Pulsed Light) treatment: in the first half of 2026, sales volume of 8,455 units, up 214% year-on-year, bringing approximately 118% more new customers to the dermatology department.

- Cross-Specialty member engagement: Promoting user movement between specialties based on user needs and in line with the customer lifecycle.

  Well-child check-ups to pediatric dentistry: Through product design that includes a pediatric dental check-up as an add-on to long-term well-child check-up packages, approximately 6,500 pediatric dental check-ups were sold in the first half of 2026. This attracted nearly 50% of customers who purchased long-term well-child check-up packages to also purchase a pediatric dental check-up, facilitating the natural transition of well-child users to pediatric dentistry as they age.

  Pediatric Eye Care and Pediatric Dentistry Cross-service Collaboration: The "Bright Eyes & White Teeth" project for children utilizes operational strategies such as product bundle add-on design and joint booking for pediatric eye and dental visits to promote mutual flow and conversion between these two services for school-age children. For instance, June 30, 2026, nearly 50% of users who purchased a long-term package for pediatric dentistry also purchased a pediatric eye care examination, driving the flow of child users between ophthalmology and dentistry.

We believe that with the ongoing improvement of One-stop Healthcare Service Institutions, the gradual maturation of our adult health management service system, and the continued enhancement of our cross-specialty membership operations, the Group will further increase user visit frequency, cross-specialty service penetration, and annual health spending, continuously unlocking customer lifetime value and creating sustainable organic growth momentum.

Membership Management: Centered on the Membership System, Deepening Long-Term Health Management Relationships

Our operations are consistently centered on our member base, and the membership system has become the core engine of our revenue growth. As of June 30, 2026, we had 124,156 active member households, and revenue contributed by member customers accounted for 78.8% of total revenue.

In the first half of 2026, through various means, we successfully converted new customers into members, adding 23,015 new member households and achieving steady growth. Our new-customer-to-member conversion rate remained at a high level of approximately 74.9%.

	Six months ended June 30,	
	2026	2025
Number of Members and Revenue Contribution		
Number of active member households	**124,156**	114,644
Proportion of revenue contributed by members	**78.8%**	72.1%
Number of new members	**23,015**	20,866
Conversion and Retention of Members		
New member conversion rate	**74.9%**	80.7%
Membership renewal rate	**67.1%**	68.9%

Notes:

1. Number of active members represents the number of member households in active membership period as of the end of the relevant reporting period;

2. The number of new members represents members newly converted from first-visit new customers and members whose expired memberships were reactivated through a new membership purchase, excluding employee welfare members and new members reactivated from existing members during the 2021 membership system reform;

3. New member conversion rate represents the proportion of new members converted from new customers for the first visit;

4. Membership renewal rate represents the number of Distinct membership accounts that were due to expire during the relevant periods (calculated as the 12 months prior to the cut-off date for comparability with annual data) and were renewed before or three months after the respective expiration dates as a percentage of the total number of Distinct membership accounts that were due to expire during the relevant periods.

We have always relied on strong word-of-mouth and member referrals as our core method for acquiring new users. In the first half of 2026, our Net Promoter Score ("**NPS**") stood at 86.9, maintaining a leading position in the industry. Our selling and marketing expenses as a percentage of revenue were 0.6%, remaining low at industry levels.

Simultaneously, we are continually exploring diversified new user acquisition strategies, including subscription-based health services, "2B2C" and content marketing. We are gradually establishing a more diverse and sustainable new user growth model to reach more families and professional elites who align with the Group's positioning.

In February 2026, we launched a health subscription service combining "innovative drugs + medical services." This service provides users with an integrated solution on top of innovative medications, encompassing "in-person consultations, enterprise WeChat consultations, CRM management, and AI empowerment," with an initial focus on weight management, gout management, and allergy solutions. Since its launch, the health subscription service has been in a rapid development stage, gradually becoming a new growth channel for the Group to acquire new customers and deepen long-term healthcare relationships with users.

Note: NPS (Net Promoter Score) is used to measure the likelihood of customers recommending a business or service to others. NPS is generated by surveys where users score our healthcare services on a rating scale of 0-10. Users'responses of nine or 10 are considered "promoters." Users' responses of six or less are considered "detractors."NPS is calculated by subtracting the percentage of respondents who are detractors from the percentage who are promoters.

AI Empowerment: Transforming Operational Tools into Service Experience Enhancements, Continuously Building AI-Native Service Capabilities

We are continuously deepening the application of AI across the entire healthcare service process. During the Reporting Period, the Group expanded the use of AI in various scenarios, including AI-assisted clinical documentation generation from consultation room audio, doctor-patient communication analysis, health check-up report interpretation, post follow-up, and customer consultations. Specifically, a concept for converting pediatric consultation audio into medical records was validated and has now entered the product integration phase. In departments such as medical aesthetics, ophthalmology, and dentistry, we are continuously exploring AI-assisted communication analysis, which supports service quality control and helps identify and codify best practices from excellent doctors in customer communication, needs identification, and empathetic service. This facilitates the replication and enhancement of these capabilities across our teams. A multi-agent assisted follow-up system has been launched and is operational nationwide. In conjunction with the development of our CRM system, the Company is also promoting AI's role in customer needs identification, service follow-up, and operational analytics to enhance service precision and synergy.

We are driving AI to evolve into a long-term health management assistant, continuously revolutionizing the user health service experience. In March 2026, the Group launched Phase I of its AI-powered Long-Term Health Record, covering child and adult health profiles, health calendars, AI-based biological age assessments, and health histories. This initiative consolidates scattered medical records, examination reports, and health indicators into more intuitive and easily understandable health information. Concurrently, the Group has initiated R&D on a next-generation personalised AI health agent. This development effort is centered on core capabilities such as user authorization, health data invocation, long-term memory, context management, task planning, and medical safety, exploring AI's evolution from an information generation tool to an intelligent agent capable of understanding customer needs, utilizing health data, and collaboratively executing service tasks.

We are strengthening our organizational AI capabilities. During the Reporting Period, the Group established an "AI Driver" mechanism to embed AI deeply into the workflows of business and functional departments. We also began constructing an internal AI Skills sharing platform and AI-first tool platform to continuously accumulate reusable knowledge assets and capability components. The Company is simultaneously developing AI full-stack engineer capabilities, exploring the use of AI to assist in requirements analysis, solution design, code generation, and automated testing. This improves the responsiveness to smaller business needs and internal tool requests, promoting the scaled application of AI capabilities within the Company.

Future Development and Strategies

Look ahead, we will focus on three core strategic initiatives:

- Accelerating the upgrade of existing Initial Standard Institutions into One-stop Healthcare Service Institutions to drive revenue growth and enhance profitability;

- Piloting subscription-based health services centered around innovative medicines and nutritional supplements to expand into new user segments;

- Leveraging our multi-specialty data and scenario advantages to develop personalized AI health assistants, creating a differentiated service experience for users.

FINANCIAL REVIEW

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Revenue	**595,909**	509,268
Cost of revenue	**(433,510)**	(393,686)
Gross profit	**162,399**	115,582
Selling expenses	**(3,754)**	(9,224)
Administrative expenses	**(126,024)**	(105,391)
R&D expenses	**(8,155)**	–
Net impairment losses on financial assets	**(1,559)**	(513)
Other income	**967**	997
Other gains – net	**1,510**	703
Finance costs – net	**(1,432)**	(5,279)
Fair value gain of convertible redeemable preference shares	**68,412**	77,622
Profit before income tax	**92,364**	74,497
Income tax (expense)/benefit	**(8,974)**	970
Profit for the period	**83,390**	75,467

1. Revenue

The Group's revenue was primarily derived from in-person healthcare services, tele-healthcare services, membership programs, and off-network healthcare services. The Group's revenue increased by 17.0% from RMB509.3 million in the first half of 2025 to RMB595.9 million in the first half of 2026, mainly due to the growth of revenue from in-person healthcare services, driven by the expansion of One-stop Healthcare Service Institution network and the enhancement of its service capabilities, the increasing of demand for multi-specialty services, and the expansion scale of our membership base.

The following table sets forth the breakdown of the Group's revenue for the periods indicated:

	Six months ended June 30,			
	2026		2025	
	Revenue *RMB'000* **(Unaudited)**	**Percentage of revenue** *%*	Revenue *RMB'000* (Unaudited)	Percentage of revenue *%*
Healthcare services				
– In-person healthcare services[1]	**549,692**	**92.3**	467,487	91.8
– Tele-healthcare services[2]	**11,993**	**2.0**	11,099	2.2
– Membership programs[3]	**11,468**	**1.9**	10,950	2.1
– Off-network healthcare services [4]	**17,543**	**2.9**	15,891	3.1
Subtotal	***590,696***	***99.1***	*505,427*	*99.2*
Others[5]	**5,213**	**0.9**	3,841	0.8
Total	**595,909**	**100.0**	509,268	100.0

Notes:

(1) Representing revenue generated from our healthcare service institutions.

(2) Representing revenue generated from our tele-healthcare service platform.

(3) Representing revenue generated from annual membership fees.

(4) Representing revenue generated from on-campus and corporate healthcare management services and medical concierge and escort services.

(5) Primarily comprising the sales of healthcare products. The healthcare products we offer primarily include (i) skincare items, (ii) oral health products, (iii) nutritional supplements, and (iv) eye and nose care products.

2. Cost of Revenue

The cost of revenue of the Group primarily consisted of employee salary and benefit expenses, depreciation and amortization, pharmaceuticals, medical consumables, and other costs. The cost of revenue increased by 10.1% from RMB393.7 million in the first half of 2025 to RMB433.5 million in the first half of 2026, mainly due to the corresponding increases in employee salaries and benefits expenses, as well as costs of pharmaceuticals and medical consumables, which were consistent with the expansion of the Group's business scale.

3. Gross Profit and Gross Profit Margin

	Six months ended June 30,			
	2026		2025	
	Gross profit	**Gross profit margin**	Gross profit	Gross profit margin
	RMB'000	*%*	*RMB'000*	*%*
	(Unaudited)		(Unaudited)	
Healthcare services				
– In-person healthcare services	**145,123**	**26.4**	98,105	21.0
– Tele-healthcare services	**2,660**	**22.2**	2,568	23.1
– Membership programs	**10,708**	**93.4**	10,121	92.4
– Off-network healthcare services	**1,142**	**6.5**	2,844	17.9
Subtotal	***159,633***	***27.0***	*113,638*	*22.5*
Others	**2,766**	**53.1**	1,944	50.6
Total	**162,399**	**27.3**	115,582	22.7

The Group's gross profit increased by 40.5% from RMB115.6 million in the first half of 2025 to RMB162.4 million in the first half of 2026. The overall gross profit margin increased by 4.6 percentage points from 22.7% in the first half of 2025 to 27.3% in the first half of 2026. The increase was primarily due to a rise in the gross profit of in-person healthcare services, which was mainly attributable to our enhanced operating efficiency and greater economies of scale.

4. Selling Expenses

The Group's selling expenses consisted of employee salary and benefit expenses, promotion and marketing expenses, and other related expenses. It decreased from RMB9.2 million in the first half of 2025 to RMB3.8 million in the first half of 2026, mainly due to: Wuhan Pleiades Children's Hospital's integration into the Group's operating and pricing system, with the Group discontinuing investment in marketing and promotion.

5. Administrative Expenses

The Group's administrative expenses consisted of employee salary and benefit expenses, depreciation and amortisation, listing expenses, healthcare institution rental expenses during the renovation period, and other related expenses. It increased by 19.6% from RMB105.4 million in the first half of 2025 to RMB126.0 million in the first half of 2026, mainly due to: (i) with the Group's business expansion, the headquarter administrative operating expenses posted a modest year-on-year increase; (ii) an increase of RMB11.8 million in listing expenses in connection with the Global Offering; (iii) an increase of RMB6.3 million in rental expenses generated by healthcare institutions during the renovation period; (iv) from July 2025, the Group implemented R&D project management rules, conducted separate accounting, and recognised the salary and benefit expenses of the R&D team under R&D expenses.

6. R&D Expenses

The Group's R&D expenses mainly consisted of employee salary and benefit expenses for the R&D team as well as third-party cooperation fees. The Group implemented R&D management rules and conducted separate accounting. The R&D expenses in the first half of 2026 were RMB8.2 million, mainly utilised for AI scenario applications and improvements to our information technology systems.

7. Net Impairment Losses on Financial Assets

The Group's net impairment losses on financial assets primarily consisted of the impairment losses on trade and other receivables. It increased from RMB0.5 million in the first half of 2025 to RMB1.6 million in the first half of 2026, mainly due to an increase in trade receivables, which was in line with the increase in revenue settled with third-party institutions.

8. Other Income

The Group's other income primarily consisted of individual income tax handling fee refunds and government subsidies. The Group's other income stayed stable in the first half of 2025 and the first half of 2026.

9. Other Gains – Net

The Group's other gains – net primarily consisted of (i) fair value gains from bank financial products, representing short-term investments in certain financial instruments issued by commercial banks; (ii) fair value losses from investment in listed equity securities; (iii) net gains on modification and early termination of leases, representing the disposal gains or losses resulting from the termination of certain leases as a result of relocation or closure of certain healthcare service institutions as recognized in accordance with the relevant accounting policies; (iv) net losses on disposal of property, plant and equipment and intangible assets; (v) forfeiture of deposits and compensation from early termination of certain leases as a result of relocation or closure of certain healthcare service institutions; and (vi) exchange gains.

The Group's other gains – net in the first half of 2026 were RMB1.5 million, primarily consisted of: (i) a gain of RMB2.8 million from bank wealth management products; (ii) a gain of RMB2.0 million arising from the revisions to rent concession for one healthcare institution each in Wuhan and Suzhou, together with the termination of leases for one healthcare institution in Wuhan; (iii) a loss of RMB3.3 million from the disposal of unamortised renovations of one closed-down healthcare institution in Wuhan and the disposal of the Group's aged property, plant and equipment.

10. Finance Costs – Net

The Group's finance costs – net primarily consisted of interest income from bank deposits and interest expenses on lease liabilities.

The net finance costs decreased by RMB3.9 million from RMB5.3 million in the first half of 2025 to RMB1.4 million in the first half of 2026, mainly due to: (i) interest income from bank deposits increased by RMB2.6 million, which was attributable to the receipt of proceeds from Global Offering and the allocation arrangement for bank wealth management products; (ii) interest on lease liabilities decreased by RMB1.3 million as a result of the revised rent-concession clauses.

11. Fair Value Gain of Convertible Redeemable Preference Shares

The Group's fair value gain of convertible redeemable preference shares decreased from RMB77.6 million in the first half of 2025 to RMB68.4 million in the first half of 2026. The decrease was primarily due to a change in the Company's equity valuation. Following the global offering of the Company completed on February 6, 2026, the convertible redeemable preference shares were automatically converted into ordinary shares.

12. Income Tax (Expense)/Benefit

The Group's income tax (expense)/benefit consisted of current income tax and deferred income tax. The increase in income tax expense to RMB9.0 million in the first half of 2026 was primarily due to the contribution from the Group's improved profitability.

13. Profit for the Period

As a result of the foregoing, the Group's net profit increased by 10.5% from RMB75.5 million in the first half of 2025 to RMB83.4 million in the first half of 2026.

14. Liquidity and Capital Resources

The Group's principal use of cash was for the upgrading and expansion of our healthcare service network, the establishment and acquisition of healthcare service institutions, as well as other working capital needs. The Group's cash and cash-like items increased from RMB535.1 million as at December 31, 2025 to RMB698.6 million as at June 30, 2026. As at June 30, 2026, the Group's cash and cash-like items comprised cash and cash equivalents, time deposits with an initial term over three months and financial assets at fair value through profit or loss, which amounted to RMB291.7 million, RMB170.4 million and RMB236.5 million, respectively.

15. Cash Flows

The table below sets forth specific figures from the Group's interim condensed consolidated cash flow statements for the periods indicated.

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Net cash generated from operating activities	**65,160**	55,237
Net cash used in investing activities	**(280,411)**	(128,981)
Net cash generated from/(used in) financing activities	**188,460**	(67,651)
Cash and cash equivalents at the beginning of the period	**324,846**	307,970
Exchange losses on cash and cash equivalents	**(6,383)**	(348)
Cash and cash equivalents at the end of the period	**291,672**	166,227

16. Gearing Ratio

The gearing ratio is calculated by dividing the total bank loans and other borrowings by the total equity as at the end of the period. As at June 30, 2026, the Group's total cash and cash equivalents and time deposits with initial terms of over three months are greater than other interest-bearing liabilities and gearing ratio is therefore not applicable.

17. Indebtedness

The Group's lease liabilities increased from RMB289.0 million as at December 31, 2025 to RMB310.0 million as at June 30, 2026, mainly due to the Group's expansion of healthcare service institutions.

18. Significant Investments, Material Acquisitions and Disposals

As at June 30, 2026, the Group did not have any significant investment, material acquisitions or disposals of subsidiaries, associates and joint ventures.

19. Contingent Liabilities

As at June 30, 2026, the Group did not have any material contingent liabilities.

20. Capital Commitments

As at June 30, 2026, the Group had capital commitments contracted but not yet provided for of RMB19.5 million, which were primarily related to the purchase of property, plant and equipment.

21. Pledge of Assets

As at June 30, 2026, the Group had not pledged or charged any assets.

22. Foreign Exchange Exposure

During the Reporting Period, the Group mainly operated in Mainland China and the majority of its transactions were settled in Renminbi, the functional currency of the Company's primary subsidiaries. The Group is exposed to foreign currency risk as a result of certain monetary assets and liabilities being denominated in non-functional currencies. The Group currently does not have a foreign currency hedging policy. However, our management monitors foreign exchange exposure and will consider hedging significant foreign currency exposure should the need arise.

23. Employees

As at June 30, 2026, the Group had 1,726 full-time employees in total, including 414 full-time doctors, and 680 other medical professionals. In strict compliance with the relevant labour laws, the Group enters into individual employment contracts with its employees covering matters such as terms, wages, bonuses, employee benefits, workplace safety, confidentiality obligations and grounds for termination.

To remain competitive in the labour market, the Group provides various incentives and benefits to its employees. The Group invests in continuing education and training programs, including internal and external training, for its management staff and other employees to upgrade their skills and knowledge. The Group also provides employees with competitive salaries and opportunities to participate in share incentive schemes. We believe our benefits, working environment and development opportunities for our employees have contributed to good employee relations and employee retention.

24. Significant Events after the Reporting Period

As at June 30, 2026 and up to the date of this announcement, the Group had no material subsequent events that took place.

OTHER INFORMATION

Interim Dividend

The Board has resolved not to declare any interim dividend for the six months ended June 30, 2026.

Corporate Governance Practices

The Group is committed to maintaining high standards of corporate governance to safeguard the interests of the Shareholders and to enhance corporate value and accountability. The Company has adopted the CG Code as its own code to govern its corporate governance practices.

Under code provision C.2.1 of Part 2 of the CG Code, the roles of chairman and chief executive should be separate and should not be performed by the same individual. Mr. WANG Zhiyuan ("**Mr. Wang**") is the chairman of the Board and the chief executive officer of the Company. With extensive experience in the financial industry and having served in the Company since its founding, Mr. Wang is in charge of making key corporate decisions and overall management of the Group. The Board considers that vesting the roles of the chairman of the Board and the chief executive officer of the Company in the same person is beneficial to the management of the Group. The balance of power and authority is ensured by the operation of the Board and the Group's senior management, which comprises experienced and diverse individuals. The Board currently comprises two executive Directors, five non-executive Directors and four independent non-executive Directors, and therefore has a strong independence element in its composition.

The CG Code was not applicable to the Company for the entire Reporting Period as the Company had not been listed on the Stock Exchange before the Listing Date. Save as disclosed above, in the opinion of the Board, the Company has complied with all the applicable code provisions set out in Part 2 of the CG Code Since the Listing Date and up to June 30, 2026. The Board will continue to review and monitor the corporate governance practices of the Company with an aim of maintaining a high standard of corporate governance.

Model Code for Securities Transactions

The Company has adopted the Model Code as its own code of conduct regarding dealings in the securities of the Company by the Directors and the relevant employees of the Company, who are likely to possess inside information in relation to the Company's securities.

The Model Code was not applicable to the Company for the entire Reporting Period as the Company had not been listed on the Stock Exchange before the Listing Date. Upon specific enquiries, all Directors confirmed that they have complied with the Model Code since the Listing Date and up to June 30, 2026. No incident of non-compliance with the Company's relevant employees had been noted since the Listing Date and up to June 30, 2026.

Sufficiency of Public Float

According to the information that is publicly available to the Company and within the knowledge of the Board, as at the date of this announcement, the Company has maintained the public float as required under the Listing Rules.

Purchase, Sale or Redemption of the Company's Listed Securities

The Board announces that the Company has adopted a share award scheme (the "**2026 Share Award Scheme**") on May 13, 2026. The Board has authorized the independent trustee of the 2026 Share Award Scheme (the "**Trustee**") to purchase no more than 1,500,000 Shares, which will be used as awards to the eligible participants under 2026 Share Award Scheme to incentivize them to make contribution to the Group. As at the date of this announcement, the Trustee has purchased an aggregate of 180,550 Shares on the market. The Trustee will, from time to time, purchase Shares on the market for grant of awards under the 2026 Share Award Scheme, subject to compliance with all applicable laws and regulations.

Save for the above, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities (including sale of treasury Shares) during the Reporting Period. The Company did not hold any treasury Shares (as defined under Listing Rules) as at June 30, 2026.

Use of Proceeds from Global Offering

In connection with the Global Offering, 4,946,100 Shares were issued at a price of HK$59.9 per Shares for a total cash consideration, after deduction of the underwriting fees and other related expenses, of approximately HK$220.1 million. Dealings in the shares of the Company on the Stock Exchange commenced on February 6, 2026. The Group will apply such proceeds in a manner consistent with the intended use of proceeds as set out in the Prospectus.

The table below sets forth the utilisation of the net proceeds from the Global Offering and the unused amount as at June 30, 2026.

Business objective as stated in the Prospectus	% of total net proceeds	Net proceeds from Global Offering	Unutilised amount as at February 6, 2026[(1)]	Actual utilised amount during the Reporting Period	Unutilized amount as at June 30, 2026[(2)]	Expected timetable for full utilization of the remaining proceeds[(3)]
		HK$ (in million)	*HK$ (in million)*	*HK$ (in million)*	*HK$ (in million)*	
Deploying advanced AI technologies to innovate healthcare delivery and operational efficiency	35.0%	77.1	77.1	6.3	70.8	December 31, 2028
– Deploying advanced AI technologies in our healthcare service business operation	15.5%	34.2	34.2	2.6	31.6	December 31, 2028
– Improvements to our own information technology systems	19.5%	42.9	42.9	3.7	39.2	December 31, 2028
Upgrading our existing healthcare service institutions and establishing new healthcare service institutions	30.0%	66.0	66	12.1	53.9	December 31, 2027

Business objective as stated in the Prospectus	% of total net proceeds	Net proceeds from Global Offering *HK$ (in million)*	Unutilised amount as at February 6, 2026[1] *HK$ (in million)*	Actual utilised amount during the Reporting Period *HK$ (in million)*	Unutilized amount as at June 30, 2026[2] *HK$ (in million)*	Expected timetable for full utilization of the remaining proceeds[3]
Acquiring healthcare service institutions in Tier-One Cities and New Tier-One Cities	25.0%	55.0	55	0.0	55	December 31, 2028
Working capital and other general corporate purposes	10.0%	22.0	22	1.8	20.2	December 31, 2027
Total	**100.0%**	**220.1**	**220.1**	**20.2**	**199.9**	

Notes:

(i) The Company was listed on February 6, 2026.

(ii) As at June 30, 2026, the unused net proceeds were deposited with certain licensed banks and financial institutions in Hong Kong or the PRC.

(iii) The expected timeline to use the remaining proceeds is prepared based on the best estimate made by the Group, which is subject to change according to the current and future development of the market condition.

Audit Committee and Review of Financial Information

The Board has established the Audit Committee with written terms of reference in compliance with Rule 3.21 of the Listing Rules and the CG Code. As at the date of this announcement, the Audit Committee comprises two independent non-executive Directors and one non-executive Director, namely Dr. GAO Pingyang (Chairperson), Ms. CHEN Rui and Mr. CAO Shaoshan. Dr. GAO Pingyang, being the chairman of the Audit Committee, holds the appropriate professional qualifications as required under Rules 3.10(2) and 3.21 of the Listing Rules. The primary duties of the Audit Committee are to review and supervise the Company's financial reporting process and internal controls.

The Audit Committee has reviewed the unaudited interim condensed financial information of the Group for the six months ended June 30, 2026 and confirmed that it has complied with all applicable accounting principles, standards and requirements, and made sufficient disclosures. The Audit Committee has also discussed the matters of audit and financial reporting.

In addition, the Company's external auditor, PricewaterhouseCoopers, has performed an independent review of the Group's interim financial information for the Reporting Period in accordance with the International Standard on Review Engagements 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity". Based on their review, PricewaterhouseCoopers confirmed that nothing has come to their attention that causes them to believe that the interim financial information is not prepared, in all material respects, in accordance with International Accounting Standard 34 "Interim Financial Reporting".

Publication of Interim Results and Interim Report

This interim results announcement is published on the website of the Stock Exchange (www.hkexnews.hk) and the Company (www.distinctclinic.com), respectively, and the interim report of the Group for the first half of 2026 containing all information required by the Listing Rules will be dispatched to the Shareholders (if requested) and published on the above websites in due course.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

	Note	Six months ended June 30, 2026 RMB'000 (Unaudited)	Six months ended June 30, 2025 RMB'000 (Unaudited)
Revenue	3	**595,909**	509,268
Cost of revenue		**(433,510)**	(393,686)
Gross profit		**162,399**	115,582
Selling expenses		**(3,754)**	(9,224)
Administrative expenses		**(126,024)**	(105,391)
Research and development expenses		**(8,155)**	–
Net impairment losses on financial assets		**(1,559)**	(513)
Other income	4	**967**	997
Other gains – net	5	**1,510**	703
Operating profit		**25,384**	2,154
Finance income	6	**3,842**	1,291
Finance costs	6	**(5,274)**	(6,570)
Finance costs – net	6	**(1,432)**	(5,279)
Fair value gain of convertible redeemable preference shares	14	**68,412**	77,622
Profit before income tax		**92,364**	74,497
Income tax (expense)/benefit	7	**(8,974)**	970
Profit for the period		**83,390**	75,467
Attributable to:			
– Owners of the Company		**86,122**	77,353
– Non-controlling interests		**(2,732)**	(1,886)
Earnings/(losses) per share for profit attributable to owners of the Company (expressed in RMB per share)			
– Basic earnings per share	8	**1.71**	5.55
– Diluted earnings/(losses) per share	8	**0.29**	*

* The losses per share is negative 0.0049.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Profit for the period	**83,390**	75,467
Other comprehensive income/(loss):		
Items that will not be reclassified to profit or loss		
Currency translation differences	**19,639**	10,039
Fair value change of convertible redeemable preference shares due to own credit risk	**(84)**	(19,885)
Items that may be subsequently reclassified to profit or loss		
Currency translation differences	**(9,213)**	(2,884)
	10,342	(12,730)
Total comprehensive income for the period	**93,732**	62,737
Attributable to:		
– Owners of the Company	**96,464**	64,623
– Non-controlling interests	**(2,732)**	(1,886)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

	Note	**As at June 30, 2026** ***RMB'000*** **(Unaudited)**	As at December 31, 2025 *RMB'000* (Audited)
Assets			
Non-current assets			
Property, plant and equipment		**216,848**	184,957
Right-of-use assets		**277,489**	252,942
Intangible assets		**146,937**	142,904
Prepayments, deposits and other receivables	10	**59,183**	42,079
Deferred income tax assets		**50,477**	50,696
Total non-current assets		**750,934**	673,578
Current assets			
Financial assets at fair value through profit or loss		**236,475**	199,366
Inventories		**43,766**	33,880
Trade receivables	9	**73,107**	69,537
Prepayments, deposits and other receivables	10	**35,546**	24,339
Term deposits with initial term of over three months	11	**170,390**	10,883
Cash and cash equivalents	11	**291,672**	324,846
Total current assets		**850,956**	662,851
Total assets		**1,601,890**	1,336,429
Equity			
Equity attributable to owners of the Company			
Share capital		**403**	85
Treasury shares		**(1,480)**	–
Reserves		**2,388,008**	(69,794)
Accumulated losses		**(1,509,892)**	(1,566,284)
		877,039	(1,635,993)
Non-controlling interests		**32,208**	34,940
Total equity/(deficit)		**909,247**	(1,601,053)

	Note	As at June 30, 2026 *RMB'000* (Unaudited)	As at December 31, 2025 *RMB'000* (Audited)
Liabilities			
Non-current liabilities			
Contract liabilities		**7,917**	4,610
Lease liabilities		**243,414**	221,110
Deferred income		**18,820**	18,820
Deferred income tax liabilities		**20**	25
Total non-current liabilities		**270,171**	244,565
Current liabilities			
Trade payables	12	**15,991**	10,528
Accruals and other payables	13	**129,515**	170,587
Contract liabilities		**196,374**	171,087
Current income tax liabilities		**13,983**	11,557
Lease liabilities		**66,609**	67,842
Convertible redeemable preference shares	14	**–**	2,261,316
Total current liabilities		**422,472**	2,692,917
Net current assets/(liabilities)		**428,484**	(2,030,066)
Total liabilities		**692,643**	2,937,482
Total equity/(deficit) and liabilities		**1,601,890**	1,336,429

NOTES TO FINANCIAL STATEMENTS

1 GENERAL INFORMATION

Distinct Healthcare Holdings Limited (the "Company") is an investment holding company. The Company and its subsidiaries (together the "Group") are principally engaged in provision of healthcare services through healthcare service institutions and tele-healthcare service platform mainly in the People's Republic of China (the "PRC").

The Company was incorporated in the Cayman Islands on February 13, 2014 as an exempted company with limited liability under the Companies Law (Cap. 22, Law 3 of 1961 as consolidated and revised) of the Cayman Islands. The address of the Company's registered office is at Floor 4, Willow House, Cricket Square, Grand Cayman KY1-9010, Cayman Islands.

The Company completed its listing on Main Board of the Stock Exchange of Hong Kong Limited on February 6, 2026.

This interim condensed consolidated financial information is presented in Renminbi ("RMB") and all amounts are rounded to the nearest thousand yuan, unless otherwise stated.

2 BASIS OF PREPARATION AND CHANGES IN ACCOUNTING POLICIES

2.1 Basis of preparation

This interim condensed consolidated financial information for the six months ended June 30, 2026 (the "Interim Financial Information") has been prepared in accordance with the International Accounting Standard 34 "Interim Financial Reporting" ("IAS 34") as issued by the International Accounting Standards Board ("IASB"). The interim report does not include all the notes normally included in annual consolidated financial statements. Accordingly, this report should be read in conjunction with the annual consolidated financial statements for the year ended December 31, 2025, which have been prepared in accordance with International Financial Reporting Standards as issued by the IASB (the "IFRS Accounting Standards"), as set out in the 2025 annual report of the Company dated March 25, 2026 (the "2025 Financial Statements").

2.2 Changes in accounting policies

The accounting policies adopted are consistent with those followed in the preparation of the 2025 Financial Statements, except for the adoption of new and amended standards as set out below.

(a) New and amended standards and interpretations adopted by the Group

The Group has applied the following standards and amendments for the first time for its annual period commencing January 1, 2026:

- Amendments to IFRS 9 and IFRS 7 — Classification and Measurement of Financial Instruments

- Amendments to IFRS 9 and IFRS 7 — Contracts Referencing Nature-dependent Electricity

- Annual Improvements to IFRS Accounting Standards – Volume 11 – IFRS 1 First-time Adoption of International Financial Reporting Standards; IFRS 7 Financial Instruments: Disclosures and its accompanying Guidance on implementing IFRS 7; IFRS 9 Financial Instruments; IFRS 10 Consolidated Financial Statements; and IAS 7 Statement of Cash Flows

The amendments listed above did not have any material impact on the amounts recognised in prior periods and are not expected to significantly affect the current or future periods.

(b) New and amended standards and interpretations not yet been adopted

The following new accounting standards and amendments to accounting standards have been published that are not mandatory for periods commencing January 1, 2026 and have not been early adopted by the Group:

		Effective for annual periods beginning on or after
IFRS 18	Presentation and Disclosure in Financial Statements	January 1, 2027
IFRS 19	Subsidiaries without Public Accountability: Disclosures	January 1, 2027
IAS 21	Translation to a Hyperinflationary Presentation Currency	January 1, 2027
Amendments to Illustrative Examples on IFRS 7, IFRS 18, IAS 1, IAS 8, IAS 36 and IAS 37	Disclosures about Uncertainties in the Financial Statements	January 1, 2027
Amendments to IFRS 10 and IAS 28	Consolidated financial statements and investments in associates and joint venture	To be determined

Except for new IFRS 18 mentioned below, the Group is commencing an assessment of the impact of these new or amended standards and interpretations, certain of which are relevant to the Group's operations. According to the preliminary assessment made by the Group, no material impact on the financial performance and position of the Group in the current or future reporting period and on foreseeable future transactions is expected when they become effective.

IFRS 18 "Presentation and Disclosure in Financial Statements"

IFRS 18 sets out requirements on presentation and disclosures in financial statements and it will replace IAS 1 Presentation of Financial Statements. The new standard introduces new requirements to present specified categories and defined subtotals in the statement of profit or loss; provide disclosures on management-defined performance measures in the notes to the financial statements and improve aggregation and disaggregation of information to be disclosed in the financial statements. Minor amendments to IAS 7 Statement of Cash Flows are also made. IFRS 18 will be effective for annual periods beginning on or after January 1, 2027, with early application permitted. The Group does not plan to early adopt IFRS 18. IFRS 18 will impact the presentation of financial statements, and is not expected to have significant impact on the financial performance and position of the Group.

3 REVENUE AND SEGMENT REPORTING

(a) The Group is principally engaged in provision of healthcare services through healthcare service institutions and tele-healthcare service platform.

The chief operating decision maker ("CODM") has been identified as the executive directors, who reviews the Group's internal reporting in order to assess performance and allocate resources. The CODM assesses the performance of the Group's business activities as a whole on a regular basis and the directors of the Company consider that the Group has only one reportable segment. Accordingly, no segment information is presented.

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Healthcare services		
– In-person healthcare services	**549,692**	467,487
– Tele-healthcare services	**11,993**	11,099
– Membership programs	**11,468**	10,950
– Off-network healthcare services	**17,543**	15,891
	590,696	505,427
Others	**5,213**	3,841
	595,909	509,268

The Group derives revenue from providing healthcare service and others at a point in time and over time as follows:

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Healthcare services		
– In-person healthcare services	**524,753**	451,715
– Tele-healthcare services	**11,993**	11,099
– Off-network healthcare services	**10,582**	9,295
	547,328	472,109
Others	**5,213**	3,841
At a point in time	**552,541**	475,950
Healthcare services		
– In-person healthcare services	**24,939**	15,772
– Membership program	**11,468**	10,950
– Off-network healthcare services	**6,961**	6,596
Over time	**43,368**	33,318
	595,909	509,268

(b) Geographical information

The Company is domiciled in the Cayman Islands while the Group operates its business mainly in Chinese Mainland and earns substantially all of the revenue from external customers in Chinese Mainland. Substantially all of the Group's identifiable assets and liabilities were located in Chinese Mainland. No geographical information is presented in accordance with IFRS 8 "Operating Segments".

(c) Information about major customers

Since none of the Group's provision of services to a single customer amounting to 10% or more of the Group's total revenue for the six months ended June 30, 2026 and 2025, no major customer information is presented in accordance with IFRS 8 "Operating Segments".

4 OTHER INCOME

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Government subsidies	**967**	997

5 OTHER GAINS – NET

	Six months ended June 30, 2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Fair value gains from bank financial products	**2,816**	3,664
Fair value losses from listed equity securities	**(316)**	(2,943)
Net gains/(losses) on modification and early termination of leases	**2,037**	(697)
Net losses on disposal of property, plant and equipment and intangible assets	**(3,270)**	(2,260)
Forfeiture of deposits and compensation from early termination of lease contracts	**(89)**	(429)
Exchange gains	**583**	2,475
Others	**(251)**	893
	1,510	703

6 FINANCE COSTS – NET

	Six months ended June 30, 2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Finance income		
– Interest income from bank deposits	**(3,842)**	(1,291)
Finance costs		
– Interest expense on lease liabilities	**5,274**	6,570
Finance costs – net	**1,432**	5,279

7 INCOME TAX (EXPENSE)/BENEFIT

	Six months ended June 30, 2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Current income tax		
– Current tax on profits for the period	**(8,760)**	(4,218)
Deferred income tax	**(214)**	5,188
	(8,974)	970

8 EARNINGS/(LOSSES) PER SHARE

(a) Basic earnings per share

Basic earnings per share is calculated by dividing the profit attributable to owners of the Company by the weighted average number of ordinary shares outstanding excluding the shares repurchased during the six months ended June 30, 2026 and 2025.

	Six months ended June 30,	
	2026	2025
	(Unaudited)	(Unaudited)
Profit attributable to owners of the Company (RMB'000)	**86,122**	77,353
Weighted average number of ordinary shares outstanding (thousand)	**50,466**	13,950
Basic earnings per share (in RMB)	**1.71**	5.55

(b) Diluted earnings/(losses) per share

Diluted earnings/(losses) per share is calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares.

For the six months ended June 30, 2026 and 2025, the Company has series of convertible redeemable preference shares and restricted share units (the "RSU") granted to employees. Diluted earnings/(losses) per share was calculated by considering the convertible redeemable preference shares could be converted into ordinary shares at the option of the holders any time. The RSU granted to employees were adjusted because the exercise price of the RSU was lower than the average market price for shares.

During the six months ended June 30, 2026, all convertible redeemable preference shares have been converted into ordinary shares pursuant to the IPO.

	Six months ended June 30,	
	2026	2025
	(Unaudited)	(Unaudited)
Profit attributable to owners of the Company (RMB'000)	**86,122**	77,353
Adjustments for the dilution effect of convertible redeemable preference shares (RMB'000)	**(68,412)**	(77,622)
Diluted profit/(loss) attributable to owners of the Company (RMB'000)	**17,710**	(269)
Weighted average number of ordinary shares outstanding (thousand)	**50,466**	13,950
Adjustments for convertible redeemable preference shares and RSU (thousand)	**10,478**	40,684
Weighted average number of shares for calculating diluted earnings/(losses) per share (thousand)	**60,944**	54,634
Diluted earnings/(losses) per share (in RMB)	**0.29**	*

* the losses per share is negative 0.0049.

9 TRADE RECEIVABLES

	As at June 30, 2026 *RMB'000* (Unaudited)	As at December 31, 2025 *RMB'000* (Audited)
Trade receivables	**76,760**	72,070
Less: allowance for impairment of trade receivables	**(3,653)**	(2,533)
	73,107	69,537

As at June 30, 2026 and December 31, 2025, the aging analysis of the trade receivables were as follows:

	As at June 30, 2026 *RMB'000* (Unaudited)	As at December 31, 2025 *RMB'000* (Audited)
Up to 60 days	**38,502**	39,583
61 days to 1 year	**30,971**	27,740
1 to 2 years	**5,860**	4,125
Over 2 years	**1,427**	622
	76,760	72,070

10 PREPAYMENTS, DEPOSITS AND OTHER RECEIVABLES

	As at June 30, 2026 *RMB'000* (Unaudited)	As at December 31, 2025 *RMB'000* (Audited)
Included in current assets		
Deposits and other receivables		
– Rental and other deposit	**3,059**	2,374
– Staff advances	**3,422**	2,713
– Others	**1,850**	340
	8,331	5,427
Less: provision for impairment of deposits and other receivables	**(136)**	(92)
	8,195	5,335
Prepayments for		
– Purchase of goods	**8,355**	2,633
– Prepaid expenses	**18,996**	13,012
– Listing expenses	**–**	3,359
	27,351	19,004
Total	**35,546**	24,339

	As at June 30, 2026 *RMB'000* (Unaudited)	As at December 31, 2025 *RMB'000* (Audited)
Included in non-current assets		
Deposits and other receivables		
– Rental and other deposit	**29,867**	26,661
	29,867	26,661
Less: provision for impairment of deposits and other receivables	**(260)**	(219)
	29,607	26,442
Prepayments for		
– Purchase of equipment and leasehold improvement	**12,702**	6,973
– Purchase of computer software	**16,874**	8,664
	29,576	15,637
Total	**59,183**	42,079

11 CASH AND CASH EQUIVALENTS

	As at June 30, 2026 *RMB'000* (Unaudited)	As at December 31, 2025 *RMB'000* (Audited)
Cash and bank deposits	**462,062**	335,729
Less: Term deposits with initial term of over three months	**(170,390)**	(10,883)
Cash and cash equivalents	**291,672**	324,846
Denominated in:		
RMB	**117,320**	206,135
USD	**340,186**	126,499
SGD	**819**	1,642
HKD	**3,535**	1,103
MYR	**201**	349
GBP	**1**	1
	462,062	335,729

12 TRADE PAYABLES

	As at June 30, 2026 *RMB'000* (Unaudited)	As at December 31, 2025 *RMB'000* (Audited)
Up to 1 year	**15,591**	10,164
Over 1 year	**400**	364
	15,991	10,528

13 ACCRUALS AND OTHER PAYABLES

	As at June 30, 2026	As at December 31, 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Employee benefits	**82,599**	115,790
Stored-value in membership accounts	**39,332**	35,384
Other taxes payable	**4,220**	3,064
Other payables for guaranteed deposits	**1,863**	3,649
Accrued listing expense payable	**473**	4,859
Others	**1,028**	7,841
	129,515	170,587

14 CONVERTIBLE REDEEMABLE PREFERENCE SHARES

	RMB'000
At January 1, 2025 (audited)	2,411,094
Fair value change of convertible redeemable preference shares due to own credit risk included in other comprehensive income	19,885
Fair value change of convertible redeemable preference shares included in profit or loss	(77,622)
Currency translation difference	(9,875)
At June 30, 2025 (unaudited)	2,343,482
Total change in fair value for the period	(57,737)
At January 1, 2026 (audited)	**2,261,316**
Fair value change of convertible redeemable preference shares due to own credit risk included in other comprehensive income	**84**
Fair value change of convertible redeemable preference shares included in profit or loss	**(68,412)**
Currency translation difference	**(22,115)**
Conversion into ordinary shares	**(2,170,873)**
At June 30, 2026 (unaudited)	**–**
Total change in fair value for the period	**(68,328)**

Upon the Listing on February 6, 2026, all convertible redeemable preference shares have been automatically converted into ordinary shares.

15 DIVIDENDS

No dividend has been paid or declared by the Company during the six months ended June 30, 2026 (six months ended June 30, 2025: nil).

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions shall have the following meanings.

"Audit Committee"	the audit committee of the Board
"Board" or "Board of Directors"	the board of Directors of the Company
"CG Code" or "Corporate Governance Code"	the "Corporate Governance Code" as contained in Appendix C1 to the Listing Rules
"China" or "PRC"	the People's Republic of China, which, for the purpose of this interim results announcement and for geographical reference only, excludes Hong Kong, the Macau Special Administrative Region of the People's Republic of China and Taiwan
"Company" or "our Company"	Distinct Healthcare Holdings Limited (卓正医疗控股有限公司), an exempted company with limited liability incorporated under the laws of the Cayman Islands, the shares of which are listed on the main board of the Stock Exchange (stock code: 2677)
"Director(s)"	the director(s) of the Company
"Distinct membership programme"	the annual fee-based membership programme launched by the Group in December 2020, offering members priority booking, discounted prices for and exclusive packages of certain healthcare services and products, and a fixed number of complimentary nurse counselling sessions
"Global Offering"	the global offering of the Shares, in connection with the listing of the Shares on the Main Board of the Stock Exchange on February 6, 2026
"Group", "our Group", "our", "we", or "us"	the Company and all of its subsidiaries
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"Hong Kong dollars" or "HK dollars" or "HK$"	Hong Kong dollars and cents respectively, the lawful currency of Hong Kong
"IFRSs"	International Financial Reporting Standards, as issued from time to time by the International Accounting Standards Board
"Listing Date"	February 6, 2026, the date of listing of the Shares on the Main Board of the Stock Exchange

"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (as amended, supplemented or otherwise modified from time to time)
"Model Code"	the "Model Code for Securities Transactions by Directors of Listed Issuers" set out in Appendix C3 to the Listing Rules
"Prospectus"	the prospectus of the Company dated January 29, 2026
"R&D"	research and development
"Reporting Period"	the six months ended June 30, 2026
"RMB"	Renminbi, the lawful currency of the PRC
"Share(s)"	ordinary share(s) in the share capital of our Company with a par value of USD0.001 each
"Shareholder(s)"	holder(s) of the Share(s)
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"%"	per cent

By order of the Board
Distinct Healthcare Holdings Limited
卓正医疗控股有限公司
WANG Zhiyuan
Chairman and Executive Director

Hong Kong, August 13, 2026

As at the date of this announcement, the Board comprises Mr. WANG Zhiyuan and Mr. SHI Yi as executive Directors; Mr. CAO Shaoshan, Mr. ZHANG Xiangdong, Mr. WEI Guoxing, Ms. CHEN Xiaohong and Mr. HAO Rui as non-executive Directors; and Ms. CHEN Rui, Mr. WANG Yonggang, Mr. WANG Gaofei and Dr. GAO Pingyang as independent non-executive Directors.